Watchmaker's New Tools Target Genomics' Costliest Bottlenecks

BOULDER, CO – June 09, 2026 – In the high-stakes world of genomic sequencing, progress is often measured in fractions of a cent per base pair. Yet, for all the advancements in raw sequencing power, the laboratories on the front lines have remained stubbornly tethered to manual, error-prone processes that inflate costs and delay discovery. Now, Boulder-based Watchmaker Genomics is making a calculated strike at these inefficiencies, announcing two new technologies designed to automate critical workflow steps and enhance data accuracy where it matters most.

At the upcoming European Society of Human Genetics (ESHG) 2026 conference, the company will debut its EquiPlex™ Normalization Kit and Equinox® Prime Library Amplification Master Mix. While the names are technical, their promise is simple: to make sequencing workflows faster, more reliable, and ultimately, more scalable. This isn't just an incremental update; it's a strategic move to address fundamental pain points that have plagued genomics research and clinical applications for years, reflecting a keen understanding of where innovation can directly impact the bottom line.

“Sequencing workflows continue to grow in scale and complexity, but many of the core bottlenecks researchers face today remain fundamentally unchanged,” said Trey Foskett, CEO of Watchmaker, in a statement. “These launches reflect our focus on engineering technologies that not only improve data quality but also simplify workflows and enable researchers to operate more efficiently at scale.”

CRISPR Beyond Editing: A New Tool for Lab Automation

The most significant source of friction in high-throughput sequencing labs often lies in a step known as library normalization. Before samples can be pooled and loaded onto a sequencer, their concentrations must be precisely equalized. Failure to do so results in wasted sequencing capacity, as some samples are overrepresented while others are barely detected, often forcing labs into costly and time-consuming re-sequencing runs.

Traditionally, this process involves a tedious cycle of quantifying each library, performing complex dilution calculations, and executing precise, variable-volume pipetting—steps that are difficult to automate and ripe for human error. Watchmaker's EquiPlex kit aims to eliminate this entire sequence. Its innovation lies in repurposing CRISPR-Cas9 technology—famous for gene editing—not as a pair of molecular scissors, but as a stoichiometric binding tool. The technology is designed to capture a fixed number of molecules from each library, regardless of its starting concentration, enabling rapid and consistent normalization in a single step.

This shift from manual adjustment to an automated, enzymatic process is a significant leap forward. “Normalization of libraries prior to pooling has always been an annoyance, especially when working at scale,” noted Graham Wiley, PhD, Director of the Clinical Genomics Center at Oklahoma Medical Research Foundation. “Our previous pipelines would often still have an amount of variability that left us needing to perform additional sequencing to reach coverage goals. With Equiplex we've finally found the level of pooling consistency we were searching for.”

By removing the need for preliminary QC and manual dilution, EquiPlex directly addresses the operational efficiency and scalability challenges highlighted by Watchmaker’s CEO. For large core facilities and clinical labs processing hundreds or thousands of samples, the reduction in hands-on time and the elimination of re-runs translate directly into lower operational costs and faster turnaround times.

The Quest for Perfect Precision in Challenging DNA

While EquiPlex tackles workflow efficiency, Watchmaker's second launch, the Equinox Prime Library Amplification Master Mix, targets an equally critical challenge: data accuracy. Next-Generation Sequencing has long struggled with certain 'dark corners' of the genome, particularly repetitive regions and homopolymers (long strings of a single base). Standard amplification enzymes can 'slip' in these areas, introducing insertion or deletion errors (indels) that can obscure true genetic variations.

This isn't just an academic problem. For clinical applications like somatic oncology, where researchers hunt for rare cancer-driving mutations or assess microsatellite instability (MSI), such errors can lead to false negatives or positives, with direct consequences for patient diagnosis and treatment. According to industry experts, nearly half of the human genome is composed of repetitive elements, making this a pervasive issue.

Equinox Prime was engineered to confront this head-on. Watchmaker claims the new master mix significantly reduces polymerase slippage in these challenging regions, improving indel accuracy without compromising on other essential metrics.

“Researchers have historically had to make trade-offs in library amplification performance, balancing yield and coverage uniformity against sequencing accuracy depending on the application,” explained Brian Kudlow, CSO of Watchmaker. “Equinox Prime was engineered to eliminate those compromises by delivering improved indel accuracy in repetitive regions alongside low error rates, high yields, and even GC coverage in a single solution.”

This 'no-compromise' approach positions Equinox Prime to compete strongly against established high-fidelity polymerases from market leaders like Roche (Kapa) and New England Biolabs. Its specific focus on indel accuracy provides a compelling value proposition for the rapidly growing clinical genomics sector, where data integrity is paramount.

Reshaping the Economics of Sequencing

Together, these two products represent a clear strategy: drive value by solving deep-seated technical problems that have direct financial and operational consequences. The genomics market is increasingly pushing towards full automation and its application in regulated clinical environments. Technologies that enhance reproducibility, reduce human error, and improve data quality are no longer just 'nice-to-haves'—they are essential for scalable growth.

Watchmaker's use of its core expertise in protein engineering to develop these solutions suggests a company focused on fundamental innovation rather than simply repackaging existing reagents. The novel application of Cas9 in EquiPlex, in particular, demonstrates a creative approach to problem-solving that could inspire new ways of tackling other lab workflow challenges.

As genomics moves further from the research bench and into the clinic, the definition of cost-effectiveness is also evolving. It's no longer just about the cost per gigabase of raw data, but the cost per meaningful result. By reducing the need for rework, minimizing errors in critical genomic regions, and streamlining labor-intensive processes, Watchmaker’s new offerings are poised to lower that effective cost, making high-quality genomic analysis more accessible and reliable. The company will showcase both technologies at its ESHG workshop in Gothenburg, Sweden, where the genomics community will get its first look at what could be a significant step forward in the industrialization of sequencing.